New combo therapy aims to improve diabetes management
NCT ID NCT07580638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at adding a drug called Chiglitazar to standard SGLT-2 inhibitor treatment for adults with type 2 diabetes whose blood sugar is not well controlled. Researchers will track changes in blood sugar, heart, kidney, and liver health over time. About 3550 participants will receive their usual care, and data will be collected from routine check-ups. The goal is to see if this combination is more effective and safe for managing diabetes long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Anti-Inflammatory diet tame type 2 diabetes?
- New diabetes combo pill aims to beat single drugs in major trial
- New triple therapy aims to protect kidneys in diabetes patients
- New combo diabetes pill tested in healthy volunteers
- New diabetes pill put to the test: does food change how it works?
- New Triple-Drug diabetes pill aims for better blood sugar control